EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP/PKA/CREB signaling

Muhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, Jaeyong Jung, Rongrong Li, Hassan Sajjad, Mark C. Koch, Kevin Lu, Junrong Yan, Barbara Rosati, Giuseppe Caso, Brinda Vallat und 16 weitere

Journal of Clinical Investigation · 19.11.2026

DOI: 10.1172/jci206802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 19.11.2026. Verfasst von Muhammad Usama Tariq und 27 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH, US Department of Veterans Affairs.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Through a genome-wide forward CRISPR/Cas9 screen in interleukin-3 (IL3)-dependent Ba/F3 cells, we identified osteoclastogenesis-associated transmembrane protein 1 (OSTM1) as a previously unrecognized tumor suppressor. Analysis of patient datasets revealed that OSTM1 is frequently deleted or downregulated in human B-cell malignancies (BCM). In mice, Cd19-Cre-driven B cell–specific monoallelic or biallelic deletion of Ostm1 cooperated with Cdkn2a loss to drive lymphomagenesis with near-complete penetrance. Mechanistically, OSTM1 directly interacts with phosphodiesterase 3B (PDE3B) and promotes its proteasomal degradation. Because PDE3B hydrolyzes cyclic AMP (cAMP), loss of OSTM1 stabilizes PDE3B, leading to suppression of tumor-suppressive cAMP-dependent PKA/CREB signaling and promotion of oncogenic transformation. Consistent with this mechanism, PDE3B is frequently amplified or upregulated in BCM, and expression of CREB/CREBBP transcriptional targets correlates positively with OSTM1 expression but inversely with PDE3B across BCM cohorts. Importantly, silencing Pde3b reverses oncogenic transformation driven by Ostm1 loss. Together, these findings establish OSTM1 as a tumor suppressor and uncover an OSTM1/PDE3B/cAMP signaling axis that restrains B-cell lymphomagenesis and may represent a therapeutically actionable vulnerability.

Förderung

  • NIH
  • US Department of Veterans Affairs

Zitieren

APA

Tariq, M. U., Sheshadri, N., Shen, J., Jung, J., Li, R., Sajjad, H., Koch, M. C., Lu, K., Yan, J., Rosati, B., Caso, G., Vallat, B., Burley, S. K., Wang, J., Glytsou, C., Sun, Y., Liu, T., Li, H., Chen, S., …, & Zong, W. (2026). OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP/PKA/CREB signaling. Journal of Clinical Investigation. https://doi.org/10.1172/jci206802

Vancouver

Tariq MU, Sheshadri N, Shen J, Jung J, Li R, Sajjad H, et al. OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP/PKA/CREB signaling. Journal of Clinical Investigation. 2026. doi:10.1172/jci206802

BibTeX
@article{Tariq2026,
  author = {Tariq, Muhammad Usama and Sheshadri, Namratha and Shen, Jianliang and Jung, Jaeyong and Li, Rongrong and Sajjad, Hassan and Koch, Mark C. and Lu, Kevin and Yan, Junrong and Rosati, Barbara and Caso, Giuseppe and Vallat, Brinda and Burley, Stephen K. and Wang, Jun and Glytsou, Christina and Sun, Yi and Liu, Tong and Li, Hong and Chen, Suzie and Yang, Jiekun and Shen, Zhiyuan and Lin, Richard Z. and Hinrichs, Christian S. and Bertoni, Francesco and Wang, Y. Lynn and Vacher, Jean and Xie, Ping and Zong, Wei-Xing},
  title = {OSTM1 restrains B-cell lymphomagenesis by promoting PDE3B degradation and activating cAMP/PKA/CREB signaling},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci206802}
}
Kostenlos starten →